Correlation Between Viking Therapeutics and Inozyme Pharma
Can any of the company-specific risk be diversified away by investing in both Viking Therapeutics and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viking Therapeutics and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viking Therapeutics and Inozyme Pharma, you can compare the effects of market volatilities on Viking Therapeutics and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viking Therapeutics with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viking Therapeutics and Inozyme Pharma.
Diversification Opportunities for Viking Therapeutics and Inozyme Pharma
0.47 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Viking and Inozyme is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Viking Therapeutics and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Viking Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viking Therapeutics are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Viking Therapeutics i.e., Viking Therapeutics and Inozyme Pharma go up and down completely randomly.
Pair Corralation between Viking Therapeutics and Inozyme Pharma
Given the investment horizon of 90 days Viking Therapeutics is expected to generate 1.41 times more return on investment than Inozyme Pharma. However, Viking Therapeutics is 1.41 times more volatile than Inozyme Pharma. It trades about -0.03 of its potential returns per unit of risk. Inozyme Pharma is currently generating about -0.3 per unit of risk. If you would invest 6,116 in Viking Therapeutics on August 28, 2024 and sell it today you would lose (917.00) from holding Viking Therapeutics or give up 14.99% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Viking Therapeutics vs. Inozyme Pharma
Performance |
| Timeline |
| Viking Therapeutics |
| Inozyme Pharma |
Viking Therapeutics and Inozyme Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Viking Therapeutics and Inozyme Pharma
The main advantage of trading using opposite Viking Therapeutics and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viking Therapeutics position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.| Viking Therapeutics vs. Terns Pharmaceuticals | Viking Therapeutics vs. Akero Therapeutics | Viking Therapeutics vs. Madrigal Pharmaceuticals | Viking Therapeutics vs. Sarepta Therapeutics |
| Inozyme Pharma vs. Eliem Therapeutics | Inozyme Pharma vs. HCW Biologics | Inozyme Pharma vs. Scpharmaceuticals | Inozyme Pharma vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |